Search+Investment IdeasGlobal brokerages remain positive on Sun Pharma and Maruti Suzuki, while staying cautious on ITC.SynopsisGlobal brokerages remained selective on large-cap stocks following the latest round of quarterly earnings, with Citi reiterating its bullish view on Sun Pharma and Morgan Stanley backing Maruti Suzuki despite trimming estimates. Meanwhile, Motilal Oswal maintained a cautious stance on ITC amid continued pressure on its cigarette business.Brokerages remained selectively optimistic on a few largecap stocks despite mixed quarterly earnings, with analysts looking beyond near-term headwinds to focus on medium-term growth drivers.While Citi reiterated its bullish stance on Sun Pharma, citing strength in its speciality business and improving traction for new launches, Morgan Stanley stayed positive on Maruti Suzuki, betting on stronger-than-guided volume growth and an eventual recovery BYETMarkets.com 5 mins readAug 03, 2026, 09:42:00 AM ISTGift this Story to your friendsFONT SIZEAbcSmallAbcMediumAbcLargeSAVEPRINTCOMMENTContinue reading with one of these options:Limited AccessFreeLogin to get access to some exclusive stories & personalised newslettersLogin NowUnlimited AccessStarting @ Rs120/monthGet access to exclusive stories, expert opinions & in-depth stock reportsSubscribe NowETUh-oh! This is an exclusive story available for selected readers only.Worry not. You’re just a step away.What’s Included withETPrime Membership
Buy, Sell or Hold: Morgan Stanley maintains buy on Maruti Suzuki; Citi retains buy on Sun Pharma
Global brokerages remained selective on large-cap stocks following the latest round of quarterly earnings, with Citi reiterating its bullish view on Sun Pharma and Morgan Stanley backing Maruti Suzuki despite trimming estimates. Meanwhile, Motilal Oswal maintained a cautious stance on ITC amid continued pressure on its cigarette business.
Citi maintains buy on Sun Pharma citing specialty business and new launches; Morgan Stanley backs Maruti betting on volume growth. Brokers look beyond near-term headwinds, signaling medium-term recovery conviction across challenged large-cap segments.







